Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMC-KRASG12V
- Development stage
- Preclinical
- Lead developer
- Immunocore
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
IMC-KRASG12V is a preclinical-stage soluble bispecific T-cell engager (ImmTAC) developed by Immunocore. It consists of an affinity-enhanced T-cell receptor (TCR) designed to target the intracellular KRAS G12V mutant peptide presented by human leukocyte antigen (HLA) alleles HLA-A*11:01 or HLA-A*03:01, fused to an anti-CD3 single-chain variable fragment (scFv). By binding to the KRAS G12V peptide-HLA complex on cancer cells and CD3 on T cells, IMC-KRASG12V redirects and activates T-cell-mediated cytotoxicity specifically against KRAS G12V-mutant tumor cells while sparing wild-type cells.
- Other names
- IMC-KRAS-G12VIMC-KRAS-G-12VIMC-KRAS-G 12V
02
Targets
CD3 (T-cell surface glycoprotein CD3)KRAS (Kirsten rat sarcoma viral oncogene homolog)
Beyond the preview
Go deeper on IMC-KRASG12V.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMC-KRASG12V.